Beta-adrenoceptor binding studies with LY195448 and metabolites

Area of Science:

• Pharmacology
• Neuroscience
• Cardiology

Background:

• LY195448(R), a phenylethanolamine derivative, exhibits in vitro cytotoxicity but caused hypotension in Phase I trials.
• Understanding the beta-adrenergic receptor binding profiles of LY195448(R) and its metabolites is crucial for its therapeutic potential and side effect management.

Purpose of the Study:

• To evaluate the competitive binding of LY195448(R), its p-hydroxy and acid metabolites, and its S-stereoisomer against the beta-adrenergic antagonist [3H]dihydroalprenolol.
• To compare the potency of LY195448(R) and its related compounds in rat brain cortex and human cardiac tissues.

Main Methods:

• Competitive binding assays using [3H]dihydroalprenolol as a radioligand.
• Evaluation of IC50 and Ki values to determine binding affinities.
• Assessment of hypotensive effects in rat models.

Main Results:

• The R-isomer of LY195448 demonstrated higher potency than the S-stereoisomer in beta-adrenergic binding.
• LY195448(R) was approximately 10-fold more active than its p-hydroxy metabolite in cardiac tissues.
• Both LY195448(R) and its p-hydroxy metabolite showed similar potency in blocking radioligand binding in the brain and reducing blood pressure in rats.
• The acid metabolite exhibited weak binding in cerebral preparations, comparable to the S-stereoisomer.

Conclusions:

• The R-isomer of LY195448 is a more potent beta-adrenergic antagonist than its S-stereoisomer.
• The p-hydroxy metabolite shares similar central and peripheral beta-adrenergic blocking activity with LY195448(R), suggesting its potential contribution to the observed hypotensive effect.
• Further investigation into the stereoselective binding and metabolic profile of LY195448 is warranted.